Cargando…
Mim8, a novel factor VIIIa mimetic bispecific antibody, shows favorable safety and pharmacokinetics in healthy adults
BACKGROUND: Mim8 (denecimig) is a novel activated coagulation factor VIII-mimetic bispecific antibody that assembles with activated coagulation FIX and FX on the platelet membrane surface. OBJECTIVES: The FRONTIER1 (NCT04204408, NN7769-4513) single ascending dose and the 4882 pharmacokinetic (PK) st...
Autores principales: | Persson, Paula, Amstrup, Anne-Beth, Coester, Hans Veit, Matytsina, Irina, Bas, Selcuk |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514552/ https://www.ncbi.nlm.nih.gov/pubmed/37745159 http://dx.doi.org/10.1016/j.rpth.2023.102181 |
Ejemplares similares
-
A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice
por: Østergaard, Henrik, et al.
Publicado: (2021) -
Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens
por: Kitazawa, Takehisa, et al.
Publicado: (2017) -
Lifetime imaging of GFP at CoxVIIIa reports respiratory supercomplex assembly in live cells
por: Rieger, Bettina, et al.
Publicado: (2017) -
A novel next‐generation FVIIIa mimetic, Mim8, has a favorable safety profile and displays potent pharmacodynamic effects: Results from safety studies in cynomolgus monkeys
por: Lauritzen, Brian, et al.
Publicado: (2022) -
Development of selective bispecific Wnt mimetics for bone loss and repair
por: Fowler, Tristan W., et al.
Publicado: (2021)